Skip to main content
Erschienen in: Annals of Nuclear Medicine 1/2020

14.11.2019 | Original Article

The prognostic role of FDG PET/CT before combined radio-chemotherapy in anal cancer patients

verfasst von: Lucia Leccisotti, Stefania Manfrida, Roberto Barone, Daria Ripani, Luca Tagliaferri, Valeria Masiello, Vanessa Privitera, Maria Antonietta Gambacorta, Vittoria Rufini, Vincenzo Valentini, Alessandro Giordano

Erschienen in: Annals of Nuclear Medicine | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

We assessed the prognostic value of several FDG PET/CT parameters, measured within the primary tumor and the involved lymph nodes, before definitive radio-chemotherapy (RCT) in anal cancer patients.

Methods

Anal cancer patients with positive baseline FDG PET/CT who underwent definitive RCT from May 2011 to February 2018 were retrospectively assessed. Primary tumour (T)-SUVmax, T-SUVpeak, T-SUVmean, T-MTV, T-TLG, whole-body (WB) MTV, and WB-TLG were measured. Kaplan–Meier curves, Cox-regression analysis, and logistic regression machine-learning technique were used to test for associations between clinical data, metabolic parameters, and outcomes as overall survival (OS), disease-specific survival (DSS), metastatic-free survival (MFS), disease-free survival (DFS), local relapse-free survival (LRFS), and colostomy-free survival (CFS).

Results

Fifty-nine patients were included in the study. Median follow-up was 28 months. Higher pre-treatment WB-MTV, T-TLG, and WB-TLG were associated with worse OS (p = 0.025, 0.021, and 0.02, respectively). PET parameters resulted also statistically significant for DSS, DFS, and CFS (p = 0.032, 0.043, 9 × 10−4 for WB-TLG). Cox analysis showed that PET parameters are significant predictors of OS, DSS, DFS, CFS, and LRFS. On multivariate analysis, age, stage, T-SUVpeak, WB-MTV, and T-TLG resulted significantly related to OS. A further stratification for patients with advanced stage (cT3-4 any N or any cT, N + ) showed that MTV and TLG, measured within the primary tumor and the involved nodes, are significantly higher in patients with a worse prognosis. In this subgroup, cut-off values of T- and WB-TLG as well as T- and WB-MTV showed a statistically significant correlation with clinical outcomes.

Conclusions

Pre-treatment metabolic parameters measured within the primary tumor and the involved nodes may represent additional new biomarkers for estimating prognosis in anal cancer patients, especially in advanced stage patients.
Literatur
2.
Zurück zum Zitat Gambacorta MA, Valentini V, Coco C, et al. Sphincter preservation in four consecutive phase II studies of preoperative chemoradiation: analysis of 247 T3 rectal cancer patients. Tumori. 2007;93:160–9.CrossRef Gambacorta MA, Valentini V, Coco C, et al. Sphincter preservation in four consecutive phase II studies of preoperative chemoradiation: analysis of 247 T3 rectal cancer patients. Tumori. 2007;93:160–9.CrossRef
3.
Zurück zum Zitat Frakulli R, Buwenge M, Cammelli S, et al. Brachytherapy boost after chemoradiation in anal cancer: a systematic review. J Contemp Brachyther. 2018;10:246–53.CrossRef Frakulli R, Buwenge M, Cammelli S, et al. Brachytherapy boost after chemoradiation in anal cancer: a systematic review. J Contemp Brachyther. 2018;10:246–53.CrossRef
4.
Zurück zum Zitat Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–21.CrossRef Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–21.CrossRef
5.
Zurück zum Zitat Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9.CrossRef Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9.CrossRef
6.
Zurück zum Zitat Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39.CrossRef Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39.CrossRef
7.
Zurück zum Zitat Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30:4344–51.CrossRef Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30:4344–51.CrossRef
8.
Zurück zum Zitat James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14:516–24.CrossRef James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14:516–24.CrossRef
9.
Zurück zum Zitat Peiffert D, Tournier-Rangeard L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941–8.CrossRef Peiffert D, Tournier-Rangeard L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941–8.CrossRef
10.
Zurück zum Zitat Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res. 2008;2:10–4.PubMedPubMedCentral Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res. 2008;2:10–4.PubMedPubMedCentral
11.
Zurück zum Zitat Martin D, Balermpas P, Winkelmann R, Rodel F, Rodel C, Fokas E. Anal squamous cell carcinoma state of the art management and future perspectives. Cancer Treat Rev. 2018;65:11–21.CrossRef Martin D, Balermpas P, Winkelmann R, Rodel F, Rodel C, Fokas E. Anal squamous cell carcinoma state of the art management and future perspectives. Cancer Treat Rev. 2018;65:11–21.CrossRef
12.
Zurück zum Zitat Benson AB, Venook AP, Al-Hawary MM, et al. Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:852–71.CrossRef Benson AB, Venook AP, Al-Hawary MM, et al. Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:852–71.CrossRef
13.
Zurück zum Zitat Bazan JG, Koong AC, Kapp DS, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med. 2013;54:27–322.CrossRef Bazan JG, Koong AC, Kapp DS, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med. 2013;54:27–322.CrossRef
14.
Zurück zum Zitat Gauthe M, Richard-Molard M, Fayard J, Alberini JL, Cacheux W, Lievre A. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer. Eur J Nucl Med Mol Imaging. 2017;44:63–70.CrossRef Gauthe M, Richard-Molard M, Fayard J, Alberini JL, Cacheux W, Lievre A. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer. Eur J Nucl Med Mol Imaging. 2017;44:63–70.CrossRef
15.
Zurück zum Zitat Mohammadkhani SS, Schmitt V, Behrendt FF, et al. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. Eur J Radiol. 2016;85:1390–4.CrossRef Mohammadkhani SS, Schmitt V, Behrendt FF, et al. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. Eur J Radiol. 2016;85:1390–4.CrossRef
16.
Zurück zum Zitat Cardenas ML, Spencer CR, Markovina S, et al. Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus. Adv Radiat Oncol. 2017;2:281–7.CrossRef Cardenas ML, Spencer CR, Markovina S, et al. Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus. Adv Radiat Oncol. 2017;2:281–7.CrossRef
17.
Zurück zum Zitat Duimering A, Riauka T, Nijjar Y, et al. Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma. Radiother Oncol. 2019;136:21–8.CrossRef Duimering A, Riauka T, Nijjar Y, et al. Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma. Radiother Oncol. 2019;136:21–8.CrossRef
18.
Zurück zum Zitat Tagliaferri L, Manfrida S, Barbaro B, et al. MITHRA - multiparametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility study. J Contemp Brachyther. 2015;7:336–45.CrossRef Tagliaferri L, Manfrida S, Barbaro B, et al. MITHRA - multiparametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility study. J Contemp Brachyther. 2015;7:336–45.CrossRef
19.
Zurück zum Zitat Kovacs G, Tagliaferri L, Valentini V. Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience. J Contemp Brachyther. 2017;9:497–8.CrossRef Kovacs G, Tagliaferri L, Valentini V. Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience. J Contemp Brachyther. 2017;9:497–8.CrossRef
20.
Zurück zum Zitat Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRef Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRef
21.
Zurück zum Zitat Kidd EA, Dehdashti F, Siegel BA, Grigsby PW. Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol. 2010;95:288–91.CrossRef Kidd EA, Dehdashti F, Siegel BA, Grigsby PW. Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol. 2010;95:288–91.CrossRef
22.
Zurück zum Zitat Deantonio L, Milia ME, Cena T, et al. Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival. Radiol Med. 2016;121:54–9.CrossRef Deantonio L, Milia ME, Cena T, et al. Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival. Radiol Med. 2016;121:54–9.CrossRef
23.
Zurück zum Zitat Rusten E, Rekstad BL, Undseth C, et al. Anal cancer chemoradiotherapy outcome prediction using (18)F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. Br J Radiol. 2019;92:20181006.CrossRef Rusten E, Rekstad BL, Undseth C, et al. Anal cancer chemoradiotherapy outcome prediction using (18)F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. Br J Radiol. 2019;92:20181006.CrossRef
24.
Zurück zum Zitat Saboo SS, Zukotynski K, Shinagare AB, Krajewski KM, Ramaiya N. Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up. Abdom Imaging. 2013;38:728–35.CrossRef Saboo SS, Zukotynski K, Shinagare AB, Krajewski KM, Ramaiya N. Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up. Abdom Imaging. 2013;38:728–35.CrossRef
25.
Zurück zum Zitat Vercellino L, Montravers F, de Parades V, et al. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. Int J Colorectal Dis. 2011;26:201–10.CrossRef Vercellino L, Montravers F, de Parades V, et al. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. Int J Colorectal Dis. 2011;26:201–10.CrossRef
26.
Zurück zum Zitat Day FL, Link E, Ngan S, et al. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Br J Cancer. 2011;105:498–504.CrossRef Day FL, Link E, Ngan S, et al. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Br J Cancer. 2011;105:498–504.CrossRef
27.
Zurück zum Zitat Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008;71:180–6.CrossRef Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008;71:180–6.CrossRef
28.
Zurück zum Zitat Akbari RP, Paty PB, Guillem JG, et al. Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Dis Colon Rectum. 2004;47:1136–44.CrossRef Akbari RP, Paty PB, Guillem JG, et al. Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Dis Colon Rectum. 2004;47:1136–44.CrossRef
29.
Zurück zum Zitat Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007;14:2780–9.CrossRef Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007;14:2780–9.CrossRef
30.
Zurück zum Zitat Tagliaferri L, Budrukkar A, Lenkowicz J, et al. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). J Contemp Brachyther. 2018;10:260–6.CrossRef Tagliaferri L, Budrukkar A, Lenkowicz J, et al. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). J Contemp Brachyther. 2018;10:260–6.CrossRef
31.
Zurück zum Zitat Tagliaferri L, Gobitti C, Colloca GF, et al. A new standardized data collection system for interdisciplinary thyroid cancer management: thyroid COBRA. Eur J Intern Med. 2018;53:73–8.CrossRef Tagliaferri L, Gobitti C, Colloca GF, et al. A new standardized data collection system for interdisciplinary thyroid cancer management: thyroid COBRA. Eur J Intern Med. 2018;53:73–8.CrossRef
Metadaten
Titel
The prognostic role of FDG PET/CT before combined radio-chemotherapy in anal cancer patients
verfasst von
Lucia Leccisotti
Stefania Manfrida
Roberto Barone
Daria Ripani
Luca Tagliaferri
Valeria Masiello
Vanessa Privitera
Maria Antonietta Gambacorta
Vittoria Rufini
Vincenzo Valentini
Alessandro Giordano
Publikationsdatum
14.11.2019
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 1/2020
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-019-01416-y

Weitere Artikel der Ausgabe 1/2020

Annals of Nuclear Medicine 1/2020 Zur Ausgabe